Research suggests another side effect of weight loss drugs could be changing the brain

The market is still pricing GLP-1s primarily as obesity and diabetes revenue stories, but the more interesting second-order effect is a behavioral optionality layer: if these agents reliably reduce compulsive consumption, they can expand into adjacent indications where willingness-to-pay is driven by relapse avoidance, not just weight loss. That creates a much larger future TAM, but it also shifts the value chain toward companies with distribution, adherence, and data feedback loops rather than pure molecule ownership. In other words, the durable winners may be the platforms that can convert one chronic prescription into multi-year patient stickiness and real-world evidence.

For incumbents, the biggest risk is not just competition in obesity, but internal cannibalization of higher-margin neuro/psychiatric or addiction-adjacent therapies if these drugs start showing broad cognitive or impulse-control effects. That is a latent threat to firms with exposure to antidepressants, sleep, and addiction franchises, because even an unapproved off-label perception can change prescribing behavior over 6-18 months. The counterpoint is that evidence remains noisy enough that the near-term revenue impact is likely concentrated in patient narratives and physician experimentation rather than formal label expansion.

The contrarian setup is that the current bullish consensus may be overestimating near-term CNS expansion while underestimating regulatory friction and long-duration safety scrutiny, especially for adolescents. If any cognitive dulling signal becomes more reproducible, the valuation multiple on GLP-1 leaders could compress even as sales keep growing. The better trade is to own the platform economics while hedging the narrative risk through short exposure to companies whose business models depend on stable appetite, alcohol, or impulse-control demand over the next 12-24 months.